The potential of DNA vaccination against tumor-associated antigens for antitumor therapy

Experimental Biology and Medicine

Volumn 227, Issue 4, 2002, Pages 227-237

  Haupt, Katharina ^a   Roggendorf, Michael ^a   Mann, Klauss ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

DNA vaccination; Immune response; Immunotherapy; Tumor

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKINE; DNA VACCINE; FLT3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GAMMA INTERFERON; TUMOR ANTIGEN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER IMMUNOTHERAPY; DRUG EFFICACY; GENETIC PREDISPOSITION; IMMUNE RESPONSE; NONHUMAN; SHORT SURVEY; TUMOR; VACCINATION;

ANIMALIA;

EID: 0036554096     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020222700403     Document Type: Short Survey

References (122)

1. Bocchia M, Bronte V, Colombo MP, Vincentis AD, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S. Antitumor vaccination: where we stand. Haematologica 85:1172-1206, 2000.
2. Ada GL. The immunological principles of vaccination. Lancet 335:523-526, 1990.
3. Weiner DB, Kennedy RC. Genetic vaccines. N Engl J Med 341:277-278, 1999.
4. Robinson HL, Torres CA. DNA vaccines. Semin Immunol 9:271- 283, 1997.
5. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity 3:165-169, 1995.
6. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 15:617-648, 1997.
7. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468, 1990.
8. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Feigner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedmann A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiver JW, Mongomery DL, Liu MA. Heterologous protection against influenza by injection of DNA encoding a viral protein Science 259:1745-1749, 1993.
9. Wang R, Doolan DL, Le TP. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282:476-480, 1998.
10. Calarota S, Bratt G, Nordlund S. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351:1320-1325, 1998.
11. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1:363-369, 1992.
12. Feltquate DM. DNA vaccines: vector design, delivery, and antigen presentation. J Cell Biochem 30-31(Suppl.):304-311, 1998.
13. Townsend A, Trowsdale J. The transporters associated with antigen presentation. Semin Cell Biol 4:53-61, 1993.
14. Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184:1555, 1996.
15. Ulmer JB, Deck RR, Dewitt CM, Donnelly JJ, Liu MA. Generation of MHC class 1-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen expression by non-muscle cells. Immunology 89:59, 1996.
16. Steinmann RM. The dendritic cell system and ist role in immunogenicity. Annu Rev Immunol 9:271, 1991.
17. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman G, Lotz M, Carson DA, Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352-354, 1996.
18. Klinman DM, Yi AK, Beaucage SI, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon-γ. Proc Natl Acad Sci U S A 93:2879-2883, 1996.
19. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 17:19-25, 1999.
20. Roman M, Martin-Orozko E, Goodman JS. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3:849-854, 1997.
21. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, Wagner H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28:2045-2054, 1998.
22. Iwasaki A, Torres CAT, Ohashi PS, Robinson HL, Barber BH. Both gene gun and intramuscular injection of plasmid DNA induce cytotoxic T-lymphocytes via bone-marrow derived antigen-presenting cells. J Immunol 159:11-14, 1997.
23. Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedmann A, Wang S, Liu X, Donnelly JJ, Liu MA. Priming of cytotoxic T-lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 3:362- 371, 1997.
24. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122-1128, 1996.
25. Iwasaki A, Cruz CSD, Young AR, Barber BH. Epitope-specific cytotoxic T lymphocyte induction by minigene DNA immunization. Vaccine 17:2081-2088, 1999.
26. Casares S, Inaba K, Brumaenu TD, Steinman RM, Bona CA. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 186:1481-1486, 1997.
27. Doe B, Selby M, Barnett S, Baenziger J, Walker CM. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived dendritic cells. Proc Natl Acad Sci U S A 93:8578-8583, 1996.
28. Ossendorp F, Mengede E, Camps M, Filus R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693-702, 1998.
29. + T cell responses in antitumor immunity. Curr Opin Immunol 10:588-594, 1998.
30. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357-2368, 1998.
31. Zöller M, Christ O. Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination. J Immunol 166:3440-3450, 2001.
32. Nawrath M, Pavlovic J, Moelling K. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model. J Mol Med 79:133-142, 2001.
33. Gu SY, Huang TM, Ruan YH, Miaou H, Lu CM, Chu M, Motz M, Wolf H. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 84:171, 1995.
34. Ertl HC, Xiang ZQ. Genetic immunization. Viral Immunol 9:1, 1996.
35. Liu MA. Vaccine developments. Nat Med 4:515, 1998.
36. Chen CH, Wang TL, Ji H, Pardoll DM, Cheng WF, Ling M, Wu TC. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther 8:128-138, 2001.
37. Danko I, Wolff JA. Direct gene transfer into muscle. Vaccine 12:1499, 1994.
38. Raz ER, Carson DA, Parker SE, Paar TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA, Baird SM, Rhodes GH. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A 91:9519-9524, 1994.
39. Anwer K, Earle KA, Shi M. Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharm Res 16:889-895, 1999.
40. Degano P, Sarphie DF, Bangham CR. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine 16:394-398, 1998.
41. Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A 90:4455-4459, 1993.
42. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci U S A 87:9568-9572, 1990.
43. Williams RS, Johnston SA, Riedy M, DeVit MJ, McElligott SG, Sanford J. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci U S A 88:2726-2730, 1991.
44. Barry MA, Johnston SA. Biological features of genetic immunization. Vaccine 15:788, 1997.
45. Larregina AT, Watkins SC, Erdos G, Spencer LA, Storkus WJ, Beer Stolz D, Falo LD. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther 8:608-617, 2001.
46. + cells after gene gun immunization. J Exp Med 188:1075-1082, 1998.
47. Akbri O, Panjwani N, Garcia SM, Tascon R, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key event for immunity. J Exp Med 189:169-178, 1999.
48. Tanigawa K, Yu H, Sun R, Nickoloff BJ, Chang AE. Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol Immunother 48:635-643, 2000.
49. Ciernik F, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing a single T cell epitope. J Immunol 156:2369-2375, 1996.
50. Drabick JJ, Glasspool-Malone J, Somiari S, King A, Malone RW. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significant enhanced by in vivo electropermeabilization. Mol Ther 3:249-255, 2001.
51. Mendiratta SK, Thails G, Eslaki NR, Thull NM, Mata M, Bronte V, Pericle F. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res 61:859-862, 2001.
52. Densmore CL, Orson FM, Xu B, Kinsey BM, Walrep JC, Hua P, Bhogal B, Knight V. Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther 1:180-188, 2000.
53. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 90:11478-11482, 1993.
54. Pertmer TM, Roberts TR, Haynes JR. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 70:6119-6125, 1996.
55. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158:2278-2284, 1997.
56. Hanke T, Neumann VC, Blanchard TJ, Sweeney P, Hill AV, Smith GL, McMichael A. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17:589-596, 1999.
57. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129, 1995.
58. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, Weiner DB. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 158:816, 1997.
59. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 58:1965-1971, 1998.
60. Chow YH, Huang WL, Chi WK, Chu YD, Tao MH. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 71:169-178, 1997.
61. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, Tao MH. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 160:1320-1329, 1998.
62. Song K, Chang Y, Prud'homme GJ. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther 7:481-492, 2000.
63. Song K, Chang Y, Prud'homme GJ. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic (CEA) studied in knockout mice. Gene Ther 7:1527-1535, 2000.
64. Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macquaques through the use of cytokine gene adjuvants. Clin Cancer Res 7:882s-889s, 2001.
65. + T cell independent antitumor immunity. Surgery 128:273-280, 2000.
66. Charo J, Ciupitu AT, Chavalier de Preville A, Trivedi P, Klein G, Hinkula J, Kiessling RA. Long-term memory obtained by genetic immunization results in fully protection from a mammary adenocarcinoma expressing an EBV gene. J Immunol 163:5913-5919, 1999.
67. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 158:1231-1237, 1997.
68. Gerloni M, Lo D, Ballou WR, Zanetti M. Immunological memory after somatic transgene immunization is positively affected by priming with GM-CSF and does not require bone marrow-derived dendritic cells. Eur J Immunol 28:1832-1838, 1998.
69. Geissler M, Schirmbeck R, Reimann J, Blum HE, Wands JR. Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mice. Hepatology 28:202-210, 1998.
70. Rakhmilevich AL, Imboden M, Hao Z, Macklin MD, Roberts T, Wright KM, Albertini MR, Yang NS, Sondel PM. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding gp100 and GM-CSF. Clin Cancer Res 7:952-961, 2001.
71. Xiang Z, Ertl HC. Mannipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129, 1995.
72. Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK. Modulation of amplitude and direction of in vivo immune responses by coadministration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 28:1089, 1998.
73. Tazi A, Bouchonnet F, Grandsaigne M, Boumsell L, Hance AJ, Soler P. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest 91:566-576, 1993.
74. Banchereau J, Steinmann RM. Dendritic cells and the control of immunity. Nature 392:245-252, 1998.
75. Fischer HG, Frosch S, Reske K, Reske-Kunz AB. Granulocytemacrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 141:3882-3888, 1988.
76. Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M, Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 61:1080-1088, 2001.
77. Lee AH, Suh YS, Sung YC. DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses. Vaccine 17:473-479, 1999.
78. Lee SW, Cho JH, Sung YC. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony stimulating factor gene. J Virol 72:8430-8436, 1998.
79. Rovero S, Boggio K, Carlo ED, Amici A, Quaglino E, Porcedda P, Musiani P, Forni G. Insertion of the DNA for the 163-171 peptide of IL1-β enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Gene Ther 8:447-452, 2001.
80. Leitner WW, Ying HY, Driver DA, Dubensky TW, Restifo NP. Enhancement of tumor-specific immune response with plasmid DNA replicon vector. Cancer Res 60:51-55, 2000.
81. Dessureault S, Graham F, Gallinger S. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 espression vector. Ann Surg Oncol 3:317-324, 1996.
82. + T cells. J Exp Med 173:759-762, 1991.
83. Corr M, Tighe H, Lee D, Dudler J, Trieu M, Brinson DC, Carson D. Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol 159:4999-5004, 1997.
84. Mendoza RB, Cantwell MJ, Kipps TJ. Immunstimulatory effects of a plasmid expression CD40 ligand (CD154) on gene immunization. J Immunol 159:5777-5781, 1997.
85. Chen CH, Wang TI, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60:1035-1042, 2000.
86. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61:3698-3704, 2001.
87. You Z, Huang X, Hester J, Toh HC, Chen SY. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 61:3704-3711, 2001.
88. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1-4, 1994.
89. Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102:1258-1264, 1998.
90. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K. Gp100/pmel 17 is a murine tumor rejection antigen: induction of self-reactive, tumoricidal T cells using high-affinity altered peptide ligand. J Exp Med 188:277-286, 1998.
91. Steitz J, Brück J, Steinbrink K, Enk A, Knop J, Tüting T. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 86:89-94, 2000.
92. Bowne WB, Srinivasan RM, Wolchok DJ. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 190:1717-1722, 1999.
93. + cytotoxic T cell response: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66:470-476, 1996.
94. Cohen EP. Cancer therapy with DNA-based vaccines. Immunol Lett 74:59-65, 2000.
95. Schreurs MW, de Boer AJ, Figdor CG, Adema GJ. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res 58:2509-2514, 1998.
96. Nawrath M, Pavlovic J, Dummet R, Schultz J, Strack B, Heinrich J, Moelling K. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17. Leukemia 13:S48-S51, 1999.
97. Wagner SN, Wagner C, Luhrs P, Waimann TK, Kutil R, Goos M, Stinge G, Schneeberger A. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. J Invest Dermatol 115:1082-1087, 2000.
98. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MARTI or gp100 for cancer therapy. J Immunol 156:700-710, 1996.
99. Park JH, Kim CJ, Lee JH, Shin SH, Chung GH, Jang YS. Effective immunotherapy of cancer by DNA vaccination. Mol Cells 9:384- 391, 1999.
100. Neglia F, Orengo AM, Cilli M, Meazza R, Tomassetti A, Canevari S, Melani C, Colombo MP, Ferrini S. DNA vaccination against the ovarian carcinoma-associated antigen folate receptor-α (Frα) induces cytotoxic T lymphocyte and antibody responses in mice. Cancer Gene Ther 6:349-357, 1999.
101. Geissler M, Wands G, Gesien A, de la Monte S, Bellet D, Wands JR. Genetic immunization with the free human chorionic gonadotropin-β subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. Lab Invest 76:859-871, 1997.
102. Pupa SM, Invernizzi AM, Forti S, Di Carlo E, Musiani P, Nanni P, Lollini PL, Meazza R, Ferrini S, Menard S. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 8:75-79, 2001.
103. Lachman LB, Rao XM, Kremper RH, Ozpolat B, Kiriakova G, Price JE. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther 8:259-268, 2001.
104. Ohwada A, Nagaoka I, Takahashi F, Tominaga S, Fukuchi Y. DNA vaccination against HuD antigen elicits antitumor activity in a small-cell lung cancer murine model. Am J Respir Cell Mol Biol 21:37-43, 1999.
105. Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA. Tyrosine hydroxylase-based DNA vaccination is effective against murine neuroblastoma. Med Pediatr Oncol 35:641-646, 2000.
106. Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Shoemaker H, Kieber-Emmons T, Agadjanyan MA, Weiner DB. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 17:3125, 1998.
107. Stevenson FK, Link CJ, Traynor A, Yu H, Corr M. DNA vaccination against multiple myeloma. Semin Hematol 36:38-42, 1999.
108. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE. Idiotype DNA vaccines against B cell lymphoma. Immunol Rev 145:211, 1995.
109. Syrengelas AT, Chen T, Levy R. DNA immunization induces protective immunity against B cell lymphoma. Nat Med 2:1038, 1996.
110. Hakim I, Levy S, Levy R. A nine-amino acid peptide from II-1β augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 157:5503, 1996.
111. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompset AR, Hamblin TJ, Radl J, Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immuneity against lymphoma and myeloma. Nat Med 4:1281, 1998.
112. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 162:4790-4795, 1999.
113. Ohashi T, Hanabuchi S, Kato H, Tateno H. Takemura F, Tsukahara T, Koya Y, Hasegawa A, Masuda T, Kannagi M. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol 74:9610-9616, 2000.
114. Jonsen AR, Durfy SJ, Burke W, Motulsky AG. The advent of the unpatients. Nat Med 2:622-624, 1996.
115. Lips CJ, Hoppener JW, Thijssen JH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem 38:168-179, 2001.
116. Haupt K, Siegel F, Lu M, Yang D, Hilken G, Mann K, Roggendorf M, Saller B. Induction of a cellular and humoral immune response against preprocalcitonin by genetic immunization: a potential new treatment for medullary thyroid carcinoma. Endocrinology 142: 1017-1023, 2001.
117. Han R, Cladel NM, Reed Ca, Peng X, Budgeon IR, Pickel M, Christensen ND. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Virol 74:9712-9716, 2000.
118. Han R, Reed CA, Cladel NM, Christensen ND. Intramuscular injection of plasmid DNA encoding cottontail rabbit papiliomavirus E1, E2, E6 and E7 induces T cell-mediated but not humoral immune responses in rabbits. Vaccine 17:1558-1566, 1999.
119. Lipford GB, Bauer S, Wagner H, Heeg K. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology 84:298-303, 1995.
120. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 6:1972-1981, 1999.
121. Velders PV, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string vaccine. J Immunol 166:5366-5373, 2001.
122. Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281:231-238, 2001.